One of the greatest challenges in modern clinical practice is that, despite the proven efficacy of many medications, a substantial proportion of patients with chronic diseases remain resistant to standard treatment. This phenomenon is closely associated with profound structural and biochemical alterations within the tissue microenvironment.

Three major factors contribute to the development of treatment resistance:

• Fibrosis – excessive connective tissue deposition creates a physical barrier that limits drug diffusion and restricts cellular activity.
• Chronic ischemia – prolonged impairment of microcirculation leads to tissue hypoxia and degeneration, reducing cellular responsiveness to growth factors and hormonal signals.
• A pro-inflammatory microenvironment – persistent immune activation accompanied by increased production of pro-inflammatory cytokines creates a hostile environment that diminishes the effectiveness of anti-inflammatory and metabolic therapies.

Together, these processes create a self-perpetuating pathological cycle:

Inflammation → Fibrosis → Ischemia → Treatment Resistance → Persistent Inflammation

In many patients, this cycle cannot be effectively interrupted using conventional pharmacological approaches alone.

Cell therapy, as a key component of regenerative medicine, offers a fundamentally different strategy. Rather than simply attempting to overcome tissue resistance, mesenchymal stem cells (MSCs) modify the tissue microenvironment itself, transforming it from a pro-inflammatory, ischemic, and fibrotic state into one that supports tissue repair and regeneration.

This process, known as tissue microenvironment modulation, helps restore tissue responsiveness to conventional pharmacotherapy, reduce medication burden, and promote long-term remission in chronic diseases.

Mechanisms of Tissue Microenvironment Modulation

Mesenchymal stem cells function as dynamic biological factories that reshape the tissue microenvironment through immunomodulation and regulation of cytokine signaling.

Immunomodulation: Macrophage Polarization

One of the principal therapeutic mechanisms of MSCs is their ability to promote the polarization of macrophages from the pro-inflammatory M1 phenotype toward the regenerative M2 phenotype, thereby supporting tissue repair and wound healing.

Pro-inflammatory M1 macrophages (classically activated)

• Produce pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and IL-12.
• Generate reactive oxygen species (ROS).
• Stimulate the activity of profibrotic fibroblasts.

Anti-inflammatory M2 macrophages (alternatively activated)

• Produce anti-inflammatory cytokines, including IL-10, TGF-β, and IL-4.
• Secrete angiogenic growth factors such as VEGF and FGF.
• Release matrix metalloproteinases (MMP-9).
• Promote tissue regeneration through regenerative cytokines and growth factors.

MSC-induced macrophage polarization is mediated through the secretion of several bioactive molecules, including:

• Prostaglandin E2 (PGE2), a potent regulator of macrophage signaling pathways.
• Transforming growth factor-β (TGF-β), a key cytokine that promotes M2 differentiation.
• Indoleamine 2,3-dioxygenase (IDO), an enzyme that contributes to immune tolerance.

As a result of this phenotypic shift, MSCs help:

• Reduce fibrosis. Matrix metalloproteinases released by M2 macrophages remodel type I collagen, facilitating the formation of new blood vessels within fibrotic tissue.
• Suppress excessive inflammatory signaling. MSCs inhibit the secretion of pro-inflammatory cytokines while increasing IL-10 production, helping interrupt the cycle of uncontrolled immune activation.
• Restore tissue homeostasis. By reactivating endogenous repair mechanisms suppressed by chronic inflammation, MSCs promote a regenerative tissue environment.

Suppression of Systemic Inflammation Through Cytokine Modulation

MSCs effectively suppress persistent inflammatory signaling and create a therapeutic window for restoring tissue homeostasis by reducing the levels of key systemic inflammatory mediators, including:

• Tumor necrosis factor-α (TNF-α) – one of the principal cytokines responsible for maintaining chronic inflammation.
• Interleukin-6 (IL-6) – a major mediator of the acute-phase response and systemic inflammation.
• Interleukin-1β (IL-1β) – a potent pro-inflammatory cytokine that initiates and amplifies inflammatory cascades.

Revascularization and Restoration of Tissue Perfusion

Chronic ischemia is more than a simple deficiency of oxygen supply. It represents a complex pathological condition characterized by impaired angiogenesis and reduced responsiveness to regulatory signaling.

MSCs help restore tissue function by secreting key regenerative growth factors, including:

Vascular Endothelial Growth Factor (VEGF)

VEGF is the primary driver of therapeutic angiogenesis. It stimulates the proliferation and migration of endothelial cells, promoting the formation of new capillaries within ischemic tissues.

Hepatocyte Growth Factor (HGF)

HGF is a multifunctional growth factor that acts on multiple cell types. It:

• activates signaling pathways that enhance endothelial cell survival under hypoxic conditions;
• exerts anti-inflammatory effects by suppressing TNF-α activity;
• promotes fibroblast migration and extracellular matrix remodeling.

Restoring Cellular Responsiveness and Overcoming Metabolic Dysfunction

In many chronic diseases, metabolic dysfunction develops as a consequence of cofactor depletion, accumulation of toxic metabolic intermediates, and impaired enzyme activity.

MSCs help overcome these metabolic barriers by activating alternative metabolic pathways and improving mitochondrial function. As a result, they enhance cellular responsiveness to regulatory signals and may contribute to improved insulin sensitivity.

Clinical Synergy: Combining MSC Therapy with Conventional Treatment

Cell-based therapies are designed to complement—not replace—established medical treatments.

Endocrinology: The Adjuvant Role of MSCs in Insulin Therapy

The use of mesenchymal stem cells as an adjunctive therapy represents one of the most promising developments in modern endocrinology. The objective is not simply to compensate for insulin deficiency but to address the underlying mechanisms of diabetes, thereby improving treatment efficacy, reducing medication requirements, and helping prevent long-term complications.

MSCs exert multiple therapeutic effects by:

• reducing chronic systemic inflammation, a major contributor to treatment resistance;
• modulating the balance between T helper 1 (Th1) and T helper 2 (Th2) immune responses;
• improving microcirculation within insulin-responsive tissues, thereby facilitating insulin delivery and utilization;
• promoting the expansion of regulatory T cells (Tregs), which help protect pancreatic islets from immune-mediated damage;
• creating a supportive microenvironment for pancreatic β-cells responsible for insulin production.

When combined with conventional insulin therapy, MSC treatment has been associated with the potential to:

• reduce inflammation and slow autoimmune destruction;
• improve tissue vascularization;
• protect cells from oxidative stress;
• enhance endogenous insulin secretion;
• improve glucose tolerance and stabilize blood glucose levels;
• reduce glucotoxicity in target tissues;
• lower glycated hemoglobin (HbA1c);
• improve the effectiveness of insulin therapy;
• decrease daily insulin requirements;
• reduce fluctuations between hypoglycemia and hyperglycemia.

Important: MSC therapy is not intended to replace insulin therapy. Instead, it serves as a complementary treatment strategy aimed at optimizing metabolic control, supporting long-term disease remission, and improving overall clinical stability.

Rheumatology and Orthopedics: Combining MSC Therapy with Conventional Treatment to Restore Cartilage Homeostasis

Healthy cartilage exists in a dynamic balance between anabolism—the synthesis of type II collagen and proteoglycans—and catabolism, the breakdown of the extracellular matrix mediated by matrix metalloproteinases.

In osteoarthritis and rheumatoid arthritis, this balance shifts toward progressive tissue degradation, resulting in collagen breakdown, cartilage deterioration, and chronic hypoxia.

The greatest therapeutic benefit can be achieved through a combined treatment approach.

MSCs provide both regenerative potential and a powerful paracrine effect. They can differentiate into chondrocytes and release exosomes that help suppress inflammation and support cartilage repair.

Conventional therapies create a favorable microenvironment for regeneration:

• Chondroprotective agents provide the building blocks required for extracellular matrix synthesis and help stabilize cartilage metabolism over time.
• Hyaluronic acid injections improve joint lubrication and provide mechanical support for newly regenerated tissue.

When conventional therapy is used alone, it may successfully control inflammation but cannot restore cartilage structure or repair the synovial membrane after years of chronic degeneration.

Conversely, MSC therapy alone may also be insufficient. Without adequate control of the inflammatory environment provided by conventional treatment, transplanted MSCs may differentiate into fibrotic tissue rather than functional chondrocytes.

In other words, conventional therapy prepares the ground, while MSC therapy plants the seeds for regeneration.

By combining MSC therapy with disease-modifying antirheumatic drugs (DMARDs), chondroprotective agents, and other standard treatments, clinicians can not only relieve symptoms but also slow cartilage degeneration, restore cartilage homeostasis, delay joint replacement surgery, and improve quality of life through better joint biomechanics.

A New Perspective on Therapeutic Potency

According to the latest ISCT 2025 (International Society for Cell & Gene Therapy) recommendations, the assessment of MSC therapeutic potential has evolved beyond the analysis of surface markers alone.

Increasing emphasis is now placed on the Potency Matrix, an approach that quantitatively evaluates the functional capacity of MSCs to modulate specific pathological processes—including immunosuppression, angiogenesis, and anti-fibrotic activity—before clinical administration.

Recent clinical studies suggest that the multimodal activity of MSCs within the tissue microenvironment may help overcome the epigenetic memory associated with chronic inflammation.

These findings also indicate that, without prior restoration of the tissue niche, conventional pharmacotherapy may remain less effective because of persistent structural and biochemical barriers.

The “Hit-and-Run” Mechanism: A Therapeutic Paradox

One of the most fascinating aspects of MSC therapy is the apparent paradox of long-lasting clinical benefits despite the short-lived presence of transplanted cells.

Following intravenous administration, circulating MSC levels typically peak within the first 2–6 hours. More than 98% of infused cells are cleared from the body within 24–48 hours.

Nevertheless, therapeutic effects—including reduced inflammation and enhanced tissue regeneration—generally become evident over the following 2–4 weeks and may persist for 6–12 months.

How can such durable clinical effects occur when the transplanted cells survive for only a few days?

The answer lies primarily in the MSC secretome—a complex mixture of soluble signaling molecules, cytokines, growth factors, and extracellular vesicles released by MSCs into the surrounding tissue microenvironment.

Among these secreted components, exosomes represent one of the most important mediators of paracrine signaling. Their nanoscale size allows them to penetrate biological barriers and reach deep tissue compartments that are often inaccessible to many conventional therapeutic agents.

Unlike isolated growth factors, exosomes carry coordinated signaling complexes capable of initiating self-sustaining regenerative cascades. They activate resident tissue cells—including macrophages, fibroblasts, and osteoblasts—stimulating prolonged production of endogenous growth factors and cytokines.

This biological amplification mechanism helps explain how a single administration of MSCs may produce therapeutic effects that last for months without repeated cell transplantation.

Reducing Pharmacological Burden Through Cell-Based Therapies

Despite the continuous development of new pharmaceuticals, modern medicine faces an increasing challenge: polypharmacy. Patients with multiple chronic conditions often require 10–15 medications daily, increasing the risk of adverse effects, drug interactions, and reduced treatment adherence.

Mesenchymal stem cells offer a fundamentally different therapeutic strategy.

Rather than simply alleviating symptoms, MSC therapy targets the underlying mechanisms of disease. By modulating the tissue microenvironment, MSCs help restore tissue responsiveness to treatment, creating conditions that support endogenous repair and regeneration.

This approach has the potential to shift clinical practice from symptom management toward pathogenesis-oriented regenerative therapy, where conventional pharmacological treatments and regenerative technologies work synergistically rather than independently.

As tissue responsiveness improves, clinicians may be able to optimize treatment regimens, reduce medication burden, and achieve more durable disease control.

Conclusion

Mesenchymal stem cells should not be viewed as a replacement for conventional pharmacotherapy. Instead, they represent a promising adjunctive therapeutic strategy capable of enhancing the effectiveness of established treatments.

By modulating the tissue microenvironment, reducing chronic inflammation, promoting angiogenesis, and supporting endogenous repair mechanisms, MSCs help restore tissue responsiveness to therapy while addressing key drivers of treatment resistance.

Growing experimental and clinical evidence suggests that combining MSC therapy with standard medical treatment may improve long-term outcomes across a range of chronic diseases. As research continues to advance, this integrative approach has the potential to become an important component of future regenerative medicine strategies.